Photobiomodulation in Chronic Fatigue Syndrome

The goal of this clinical trial is to evaluate whether photobiomodulation therapy (low-level laser therapy) can reduce fatigue and improve quality of life in patients with chronic fatigue syndrome (CFS). The study will include adults aged 18-60 years diagnosed with chronic fatigue syndrome. The main questions it aims to answer are: Does photobiomodulation therapy significantly reduce fatigue levels as measured by the Fatigue Severity Scale (FSS) and Multidimensional Fatigue Inventory (MFI-20)? Does photobiomodulation therapy improve pain, functional capacity, sleep quality, and psychological well-being in patients with chronic fatigue syndrome? Researchers will compare the low-level laser therapy group with a placebo (sham laser) group to determine whether photobiomodulation therapy leads to greater improvements in fatigue, pain, and overall quality of life. Participants will: Receive either active low-level laser therapy or placebo treatment three times per week for eight weeks Undergo assessments of fatigue, pain, functional capacity, quality of life, sleep quality, and psychological well-being at baseline and follow-up intervals (3, 6, and 12 months)

Inclusion Criteria: Diagnosis of CFS according to the 2015 Institute of Medicine criteria Fatigue Severity Scale (FSS) score ≥ 4 Ability to understand study procedures and provide informed consent Exclusion Criteria: Comorbid psychiatric conditions (e.g., major depression, schizophrenia) Current use of corticosteroids or immunomodulators Known photosensitivity or dermatologic contraindications to LLLT Participation in structured exercise programs more than twice weekly Diagnosed malignancy or active infection Not willing to be the part of study